Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX in Locally Advanced Gastric Cancer
NCT03825861Phase 2Recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Feb 2017
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and fluorouracil in gastric cancer (GC), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Pathologic Complete Response. Started Feb 2017; status: recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03825861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825861.